Clinical Trials
74 trialsInvestigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
AstraZeneca
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Chinese PLA General Hospital
Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy
Cairo University
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
SCARF-1
Karolinska Institutet
VICD
Medical College of Wisconsin
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
Brigham and Women's Hospital
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
TSTENT
Rabin Medical Center
TRIABETES
University of Pittsburgh
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
National Institute of Cancerología
DREAMM12
GlaxoSmithKline
IREKI
Institut du Cancer de Montpellier - Val d'Aurelle
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
University of California, Los Angeles
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
CKD AGE
Centre Hospitalier Saint Joseph Saint Luc de Lyon
SELF-BREATHE RCT for Chronic Breathlessness
King's College Hospital NHS Trust
STONE
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CECIL
University of Santo Tomas Hospital, Philippines
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
AstraZeneca
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Tanabe Pharma America, Inc.
BRIDGE
Oncopeptides AB
POM Renal
Celgene
Mesenchymal Stem Cells After Renal or Liver Transplantation
University of Liege
LVPK
BTG International Inc.
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
OPTIMAL
Oxford University Hospitals NHS Trust
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
OPTI-AGED
Centre Hospitalier Universitaire de Saint Etienne
Study of Copanlisib in Hepatic or Renal Impairment
Bayer
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Novartis
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Massachusetts General Hospital
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
RENAL
Celgene
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
National Cancer Institute (NCI)
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline